FDA's top drug official told lawmakers Thursday (May 9) that firms falling under a proposed new category of compounding manufacturing should maintain a state pharmacy license to keep drug manufacturers from edging into this new class, as stakeholders further debated how to draw jurisdictional . . .
No comments:
Post a Comment